176 related articles for article (PubMed ID: 22225412)
1. S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects.
Ishima Y; Chen D; Fang J; Maeda H; Minomo A; Kragh-Hansen U; Kai T; Maruyama T; Otagiri M
Bioconjug Chem; 2012 Feb; 23(2):264-71. PubMed ID: 22225412
[TBL] [Abstract][Full Text] [Related]
2. Tuning of poly-S-nitrosated human serum albumin as superior antitumor nanomedicine.
Ishima Y; Fang J; Kragh-Hansen U; Yin H; Liao L; Katayama N; Watanabe H; Kai T; Suenaga A; Maeda H; Otagiri M; Maruyama T
J Pharm Sci; 2014 Jul; 103(7):2184-2188. PubMed ID: 24846171
[TBL] [Abstract][Full Text] [Related]
3. S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes.
Kinoshita R; Ishima Y; Ikeda M; Kragh-Hansen U; Fang J; Nakamura H; Chuang VT; Tanaka R; Maeda H; Kodama A; Watanabe H; Maeda H; Otagiri M; Maruyama T
J Control Release; 2015 Nov; 217():1-9. PubMed ID: 26302904
[TBL] [Abstract][Full Text] [Related]
4. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
[TBL] [Abstract][Full Text] [Related]
5. Design and evaluation of S-nitrosylated human serum albumin as a novel anticancer drug.
Katayama N; Nakajou K; Komori H; Uchida K; Yokoe J; Yasui N; Yamamoto H; Kai T; Sato M; Nakagawa T; Takeya M; Maruyama T; Otagiri M
J Pharmacol Exp Ther; 2008 Apr; 325(1):69-76. PubMed ID: 18218831
[TBL] [Abstract][Full Text] [Related]
6. Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models.
Ishima Y; Hara M; Kragh-Hansen U; Inoue A; Suenaga A; Kai T; Watanabe H; Otagiri M; Maruyama T
J Control Release; 2012 Nov; 164(1):1-7. PubMed ID: 23063551
[TBL] [Abstract][Full Text] [Related]
7. Cellular uptake mechanisms and responses to NO transferred from mono- and poly-S-nitrosated human serum albumin.
Ishima Y; Yoshida F; Kragh-Hansen U; Watanabe K; Katayama N; Nakajou K; Akaike T; Kai T; Maruyama T; Otagiri M
Free Radic Res; 2011 Oct; 45(10):1196-206. PubMed ID: 21781009
[TBL] [Abstract][Full Text] [Related]
8. Drug Delivery System for Refractory Cancer Therapy via an Endogenous Albumin Transport System.
Ishima Y; Maruyama T; Otagiri M; Ishida T
Chem Pharm Bull (Tokyo); 2020; 68(7):583-588. PubMed ID: 32611995
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis induction of poly-S-nitrosated human serum albumin in resistant solid tumor under hypoxia can be restored by phosphodiesterase 5 inhibition.
Ikeda M; Ishima Y; Chuang VTG; Ikeda T; Kinoshita R; Watanabe H; Ishida T; Otagiri M; Maruyama T
Nitric Oxide; 2017 Sep; 69():28-34. PubMed ID: 28414103
[TBL] [Abstract][Full Text] [Related]
10. Albumin-Based Nitric Oxide Traffic System for the Treatment of Intractable Cancers.
Ishima Y
Biol Pharm Bull; 2017; 40(2):128-134. PubMed ID: 28154250
[TBL] [Abstract][Full Text] [Related]
11. Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy through the generation of nitric oxide.
Ishima Y; Inoue A; Fang J; Kinoshita R; Ikeda M; Watanabe H; Maeda H; Otagiri M; Maruyama T
Cancer Sci; 2015 Feb; 106(2):194-200. PubMed ID: 25457681
[TBL] [Abstract][Full Text] [Related]
12. Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells.
Katayama N; Nakajou K; Ishima Y; Ikuta S; Yokoe J; Yoshida F; Suenaga A; Maruyama T; Kai T; Otagiri M
Nitric Oxide; 2010 May; 22(4):259-65. PubMed ID: 19818866
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
14. One-step preparation of S-nitrosated human serum albumin with high biological activities.
Ishima Y; Hiroyama S; Kragh-Hansen U; Maruyama T; Sawa T; Akaike T; Kai T; Otagiri M
Nitric Oxide; 2010 Sep; 23(2):121-7. PubMed ID: 20451647
[TBL] [Abstract][Full Text] [Related]
15. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.
Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
Anticancer Drugs; 1999 Sep; 10(8):785-90. PubMed ID: 10573211
[TBL] [Abstract][Full Text] [Related]
16. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier.
Prakash J; de Jong E; Post E; Gouw AS; Beljaars L; Poelstra K
J Control Release; 2010 Jul; 145(2):91-101. PubMed ID: 20362019
[TBL] [Abstract][Full Text] [Related]
17. Development of polyethylene glycol-conjugated poly-S-nitrosated serum albumin, a novel S-Nitrosothiol for prolonged delivery of nitric oxide in the blood circulation in vivo.
Katsumi H; Nishikawa M; Yamashita F; Hashida M
J Pharmacol Exp Ther; 2005 Sep; 314(3):1117-24. PubMed ID: 15901798
[TBL] [Abstract][Full Text] [Related]
18. [Human Serum Albumin as Carrier in Drug Delivery Systems].
Ishima Y; Maruyama T
Yakugaku Zasshi; 2016; 136(1):39-47. PubMed ID: 26725666
[TBL] [Abstract][Full Text] [Related]
19. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.
Maeda H
Bioconjug Chem; 2010 May; 21(5):797-802. PubMed ID: 20397686
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors.
Hornick JL; Khawli LA; Hu P; Sharifi J; Khanna C; Epstein AL
Clin Cancer Res; 1999 Jan; 5(1):51-60. PubMed ID: 9918202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
